Combining HDAC Inhibitors With Immunotherapy in Melanoma
Sanjiv S. Agarwala, MD, chairman of medical oncology at St. Luke’s University Health Network, discusses the combination of immunotherapy and a histone deacetylase inhibitor in patients with melanoma, as well as other types of cancer.
Sanjiv S. Agarwala, MD, chairman of medical oncology at St. Luke’s University Health Network, discusses the combination of immunotherapy and a histone deacetylase (HDAC) inhibitor in patients with melanoma, as well as other types of cancer.
Agarwala says that HDAC/immunotherapy combinations, such as seen with pembrolizumab (Keytruda) plus entinostat, could have promise in other diseases in addition to melanoma. Entinostat could also be combined with nivolumab (Opdivo) or other PD-1/PD-L1 antibodies, Agarwala says.
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More
